CMS is adding value-based care (VBC) risk faster than many providers can build the data and tech capacity they need to succeed.
|Articles|August 22, 2014
ACS Exec Exits After Projecting $40-Million Revenue Slump
Advertisement
Last summer the
The society stated in a press release at that time that adding MacMaster to the "seminal post" was "... part of a transformative effort designed to save even more lives from cancer."
Less than 18 months later that executive is gone, and the ACS is facing a projected $40-million revenue loss linked to an especially poor showing from its hallmark
events.
Source: MedPage Today
Read the full story:
Advertisement
Related to this article
Phase 3 wins for ianalumab and dazodalibep bring targeted therapies closer for Sjögren disease as patients face diagnostic delays and high costs.
Patch testing in Malaysia finds contact dermatitis drivers in chronic hand eczema—nickel and fragrance allergy lead, while cosmetics raise polysensitization risk.
Coverage of our peer-reviewed research and news reporting in the health care and mainstream press.
Although PMOS Awareness Month has ended, the conversation continues, with experts saying closing diagnostic and care gaps requires ongoing efforts.
Among people with HIV, lung cancer screening eligibility rose from 6% to 15% in 6 years, but uptake stayed under 30%.
CMS finalized the mandatory GLOBE Model, tying Part B drug rebates to international prices in areas covering 25% of beneficiaries from Jan. 1, 2027.
New data on atopic dermatitis show treatment gaps, heavy reliance on dermatology APPs, and wide state variation in specialist supply
Advertisement
Advertisement
Trending on AJMC
1
Lung Cancer Screening Lags for People With HIV as Eligibility Triples
2
VYD2311 Shows Superior Safety vs mRNA COVID-19 Vaccine
3
CMS Finalizes Mandatory GLOBE Model to Test Lower Part B Drug Costs
4
Dual Agonist Survodutide Delivers Up to 13.1% Weight Loss in T2D
5